For orthopedic trauma, joint replacements, and oncology-related surgical procedures
Osteotech has reported that Plexur M (moldable) has been approved for use by 50 US hospitals to date. The company expects to receive additional approvals as Plexur M continues to gain mindshare among surgeons.
Plexur M is a bone-polymer composite of bioresorbable polymer and cortical bone fibers used in a variety of orthopedic procedures. Plexur M is highly differentiated from competing products by being the only radiopaque, moldable, settable and machinable bone graft implant that completely remodels into new bone.
Plexur M is a bone-polymer biocomposite of bioresorbable polymer and cortical bone fibers, built upon the company’s proprietary Plexur technology platform, may be used in a variety of orthopedic procedures.
Plexur M is moldable, settable, machinable and radiopaque and fully remodels into new host bone. Plexur M provides exceptional handling characteristics.
Sam Owusu-Akyaw, president and chief executive officer of Osteotech, said: “Since the advent of the controlled release in the US Plexur M has been used in a range of surgical procedures and is building a reputation as a go-to biologic for orthopedic surgeries requiring tailored solutions.
“As we have continued to communicate the differentiating advantages that Plexur M offers, we have gained mindshare among orthopedic surgeons focused on orthopedic trauma, joint replacements, and oncology-related procedures.”
David Lewallen, chair of orthopedic surgery at the Mayo Clinic in Rochester, Minnesota, said: “Plexur M has been very helpful in procedures involving uncontained defects where restoration of bone and avoidance of soft tissue impingement against the underlying implant is wanted. Short-term radiographic appearance is gratifying and long-term follow-up is ongoing.”